Tredaptive: Phase III data

The investigator-led, double-blind, placebo-controlled, European and Chinese Phase III HPS2-THRIVE trial in 25,673 patients at high risk for cardiovascular events showed that Tredaptive plus statin therapy missed the primary endpoint of reducing the composite of coronary death, non-fatal MI, stroke or revascularization vs. statin therapy alone. Tredaptive plus statin therapy also significantly increased the incidence of certain types of non-fatal serious adverse events vs. statin therapy alone, but did not disclose details. Detailed data are expected in 1Q13. The trial was conducted by researchers at Oxford University and funded by Merck. ...